Author Archives: Bruno Quinney

Osteoarthritis
#Clinical trial #Osteoarthritis

Osteoarthritis treatment could reduce pain by half 

A treatment for osteoarthritis (OA) could slash pain by half and limit stiffness and other debilitating symptoms, a study shows.  LEVI-04, developed by biotechnology company Levicept, is a first-in-class treatment for OA which led to a 50% reduction in pain for patients participating in a Phase II study. Read More

#News

Clinical trial
#AI #Clinical trials #ICON

Partnership set to make therapies ‘reach patients sooner’ 

A new partnership could accelerate clinical trials and bring therapies to patients sooner.  Clinical research organisation ICON has partnered with Advarra to introduce a new ‘research-ready’ site network model for clinical trials, set to address major bottlenecks.  The partnership will integrate ICON’s global clinical trial solutions and… Read More

#News

Bacteria in Petri dishes
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Covid-19 #mRNA #mRNA-based vaccines #Oncology #RNA

How drug discovery is tackling global health challenges

This is the latest episode of the free DDW Narrated Podcast. The episode covers two articles written for DDW Volume 25, Issue 2, Spring 2024. The first article is called ‘Why more work is needed to fight antimicrobial resistance’. In the article, DDW Editor Reece Armstrong speaks to Professor… Read More

#Featured Podcasts

#Cellular assays #High Throughput #Semarion

Semarion raises $3.8m to scale cell assay technology 

Semarion has raised $3.8 million to scale its next-generation cell assay technology and expand manufacturing of its microcarrier platform.  The company, a University of Cambridge spin-out from the Cambridge Laboratory, will use investment to facilitate commercial expansion and scale manufacturing of its SemaCyte platform, which enables adherent cell models to be handled as assay-ready,… Read More

#Business & Investment #News

Cancer patient receives chemotherapy via IV
#Clinical trial #Skin cancer

Therapeutic could help skin cancer patients avoid surgery 

A new therapeutic could help patients with non-melanoma skin cancer avoid immediate surgery, data shows.  The Phase II SkinJect dataset, released by biotech company Medicus Pharma, shows microneedle-mediated delivery of doxorubicin led to a response rate of approximately 80%.  The study, which compared doxorubicin compared with a… Read More

#Cancer Research #News

#ABPI #Clinical trials #GLP-1 #Immune response #NHS #Obesity #Oncology #Prostate cancer #T cell #Texas A&M University Health Science Center #Weight loss

DDW Highlights: 31 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates the key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a study found obesity could be treated in other ways than through drugs… Read More

#Podcasts

#ABPI #Clinical trials #Dementia #GLP-1 #Immune response #Neuroscience #NHS #Obesity #Oncology #Prostate cancer #T cell #Texas A&M University Health Science Center #Tregs #Weight loss

This week in Drug Discovery (23 – 27 March) 

News round-up for 23 – 27 March by Bruno Quinney, Content Team at DDW.  This week, obesity could be treated in other ways than through drugs suppressing appetite. Elsewhere, prostate cancer has been a central theme in cancer research.   The top stories:    Obesity… Read More

#News

Cancer research
#Alpha-1 antitrypsin deficiency #Beam Therapeutics #Biotech

Beam reports positive data for genetic disease treatment 

Biotechnology company Beam Therapeutics has reported encouraging data for its treatment for the genetic disease Alpha-1 Antitrypsin Deficiency (AATD).  Beam announced BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation designed to directly correct the underlying genetic mutation that causes AATD, has shown a well-tolerated safety profile and efficacy in a… Read More

#News

Screening patient for AMD
#Clinical trial #Geographic atrophy

First patient dosed in trial of Geographic Atrophy treatment 

The first patient has been dosed in a first-in-human clinical trial of a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).  CTx001, developed by biotechnology company Complement Therapeutics, is being evaluated in the Phase I/II Opti-GAIN study evaluating its safety, tolerability and preliminary efficacy. … Read More

#News

#In vivo #Pharmacology #Sygnature Discovery

Sygnature Discovery appoints new Head of In Vivo Pharmacology 

CRO Sygnature Discovery has announced the appointment of Susanne Back as Head of In Vivo Pharmacology.  Back has 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River. She will lead one of Sygnature’s in vivo pharmacology… Read More

#News

Map of China
#China #Radiopharmaceuticals

Radspherin receives patent protection in China 

The China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin, a radiopharmaceutical treating micrometastases in cancer patients.  Radspherin, developed by biotechnology company Oncoinvent, is a receptor-independent alpha radiation therapy that destroys residual micrometastases using a single, highly localised dose of alpha radiation.  … Read More

#News

#Cancer research #Collaboration #Organoids

Global collaboration aims to create safer cancer therapeutics 

An international collaboration is set to evaluate chemotherapeutic toxicity in human organoids, aiming to generate safer and more effective cancer therapeutics.  iXCells Biotechnologies, a provider of human cell-based solutions and iPSC services, has announced it has joined the collaboration alongside Rosebud Biosciences, Kantify and Incite. The project will… Read More

#Cancer Research #News

#Cancer research #Drug discovery #Enzymes #Myeloma #Parkinson's #University of Edinburgh

DDW Highlights: 26 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates the key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a cancer enzyme discovery provided clues for potential new treatments. Elsewhere, how can… Read More

#Podcasts

#GLP-1 #Obesity #Weight loss

Obesity could be treated without suppressing appetite 

Obesity could be treated in other ways than using drugs suppressing appetite, a study reveals.  Researchers identified how brown fat cells, which are linked to weight loss, communicate to expand nerve and blood vessel networks, boosting heat generation. The findings, published in Nature Communications, hint at new ways… Read More

#News

Theranostic radiopharmaceuticals
#Drug discovery #Radiopharmaceuticals

New protein drugs could pave way for faster drug development 

A new class of protein drugs have shown amenability to multiple isotopes, paving the way for faster radiopharmaceutical drug development.  Biotechnology company Molecular Partners announced preclinical data showing its Radio-DARPins are suitable to different isotopes, each specific for a different tumour target.   DARPin (Designed Ankyrin Repeat Protein)… Read More

#News

Prostate cancer cells
#Immune response #Prostate cancer #T cell

‘Supercharged’ T cells could improve prostate cancer treatment 

Scientists have engineered new ‘supercharged’ immune cells that could attack prostate cancer more effectively.  Researchers at UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, have engineered a new class of ‘supercharged’ T cells that are stronger, longer lasting, and… Read More

#Cancer Research #News